Trial Profile
An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 22 Aug 2022 Status changed from active, no longer recruiting to completed.
- 11 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 03 May 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.